The relevance of psychotherapeutic-pharmacological combination therapies in anxiety disorders;Zum Stellenwert psychotherapeutisch-pharmakologischer Kombinationstherapien bei Angststörungen

Verhaltenstherapie

Volumn 8, Issue 3, 1998, Pages 160-169

  Angenendt, J ^a   Frommberger, U ^a   Berger, M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Anxiety disorders; Cognitive behavioral therapy; Combined therapy; Exposure treatment; Psychopharmacotherapy

Indexed keywords

EID: 17344363643     PISSN: 10166262     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030642     Document Type: Article

References (67)

1. Bandelow B, Sievert K, Rothemeyer M, Hajak G, Brooks A, Rüthen E: Panic disorder and agoraphobia. What is effective? Fortschr Neurol Psychiatrie 1995;63:451-464.
2. Barlow DH: The role of cognitive-behavioral therapy in an integrated treatment; in Rosenbaum JF (ed): Panic disorder. Making clinical sense of the latest research. J Clin Psychiatry 1997;58:131-134.
3. Barlow DJ, Lehmann CL: Advances in the psychosocial treatment of anxiety disorders. Implications for national health care. Arch Gen Psychiatry 1996;53: 727-735.
4. Brown TA, Barlow DH: Long-term outcome in cognitive-behavioral treatment of panic disorder: Clinical predictors and alternative strategies for assessment. J Consult Clin Psychol 1995;63:754-765.
5. Bruce TJ, Spiegel DA, Gregg SF, Nuzzarello A: Predictors of alprazolam discontinuation with an without cognitive therapy in panic disorder. Am J Psychiatry 1995;152:1156-1160.
6. Clark DB, Agras WS: The assessment and treatment of performance anxiety in musicians. Am J Psychiatry 1991;148:598-605.
7. Clark DM, Salkovskis PM, Hackmann A, Middleton H, Anastasiades P, Gelder M: A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. Br J Psychiatry 1994;164: 759-769.
8. Clum GA: Psychological interventions vs drugs in the treatment of panic. Behav Ther 1989;20:429-457.
9. Cohen SD, Monteiro W, Marks IM: Two-year follow-up of agoraphobics after exposure and imipramine. Br J Psychiatry 1984;144:276-281.
10. Cottraux J, Note ID, Cungi C, Légeron P, Heim F, Chneiweiss L, Bernand G, Bouvard M: A controlled study of cognitive therapy with buspirone or placebo in panic disorder with agoraphobia. Br J Psychiatry 1995;167:635-641.
11. de Beurs E, van Balkom AJ, Lange A, Koele P, van Dyck R: Treatment of panic disorder with agoraphobia: Comparison of fluvoxamin, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. Am J Psychiatry 1995;152:683-691.
12. Falloon IRH, Lloyd GG, Harpin RE: The treatment of social phobia. J Nerv Ment Dis 1981;169:180-184.
13. Fava GA, Savron G, Zielezny M, Grandi S, Rafanelli C, Conti S: Overcoming resistance to exposure in panic disorder with agoraphobia. Acta Psychiatr Scand 1997;95:306-312.
14. Frommberger U, Angenendt J, Berger M: Die Behandlung von Panikstörungen und Agoraphobien. Pharmakotherapie. Psychotherapie und deren Kombination. Nervenarzt 1995;66:173-186.
15. Fyer AJ, Liebowitz MR, Gorman JM, Campeas R, Levin A, Davies SO, Goetz D, Klein DF: Discontinuation of alprazolam treatment in panic patients. Am J Psychiatry 1987;144:303-308.
16. Gelernter CS, Uhde TW, Cimbolic P, Arnhoff DB, Vittone BJ, Tancer ME, Bartko JJ: Cognitive-behavioral and pharmacological treatments of social phobia: A controlled study. Arch Gen Psychiatry 1991;48:938-945.
17. Gould RA, Otto MW, Pollack MH: A meta-analysis of treatment outcome for panic disorder. Clinical Psychol Rev 1995;15:819-844.
18. Hafner RJ, Marks IM: Exposure in vivo of agoraphobics: Contributions of diazepam, group exposure, and anxiety evocation. Psychol Med 1976;6:71-88.
19. Hand I: Verhaltenstherapie und Psychopharmaka bei Phobien? Welche Konsequenzen hat die «Entdeckung» der Panic-Disorder wirklich für die verhal-tenstherapeutische Praxis und Forschung? in Götze P (Hrsg): Leitsymptom Angst. Berlin, Springer, 1984, pp 127-150.
20. Hand I, Angenendt J, Fischer M, Wilke C: Exposure in vivo with panic management for agoraphobia: Treatment rationale and long-term outcome; in Hand I, Wittchen HU (Hrsg): Panic and Phobias. Berlin, Springer, 1984, pp 104-127.
21. Hegel MT, Ravaris CL, Ahles TA: Combined cognitive behavioral and time-limited alprazolam treatment of panic disorder. Behav Ther 1994;25:183-195.
22. Ho fart A, Due-Madsen J, Lande B, Gude T, Bille H, Torgersen S: Clomipramine in the treatment of agoraphobic inpatients resistant to behavioral therapy. J Clin Psychiatry 1993;54:481-487.
23. Hoffmann SO, Bassler M: Stationäre Psychotherapie bei Angststörungen - ein Vergleich ihrer therapeutischen Wirkung bei Patienten mit generalisierter Angststörung, Agoraphobie und Panikstörung. Psychother Psychosom Med Psychol 1994;44:217-225.
24. Hollon SD, Shelton RC, Loosen PT: Research considerations in evaluating combined treatment; in Beitman BD, Klerman GL (eds): Integrating Pharmacotherapy and Psychotherapy. Washington, American Psychiatric Press, 1991, pp 353-375.
25. Jefferson JW: Social phobia: A pharmacologic treatment overview. J Clin Psychiatry 1995;56(suppl 5):18-25.
26. Jefferson JW: Antidepressants in panic disorder. J Clin Psychiatry 1997;58(suppl 2):20-24.
27. Judd LL: The NIMH research program in panic disorder: The present and future. J Psychiatric Res 1994; 27(suppl):221-228.
28. Lelliott PT, Marks IM, Monteiro WO, Tsakiris F, Noshirvani H: Agoraphobics 5 years after imipramine and exposure. J Nerv Ment Dis 1987;175:599-605.
29. Lipsedge MS, Hajioff J, Huggins P, Napier L, Pearce J, Pike DJ, Rich M: The management of severe agoraphobia: A comparison of iproniazid and systematic densitivation. Psychopharmacologia 1973;32:667-680.
30. Marks IM: Fears, Phobias, and Rituals. Anxiety and Their Disorders. New York, Oxford University Press, 1987.
31. Marks IM: Gegenwärtiger Stand son Reizkonfrontation («Exposure») und Reizüberflutung («Flooding»). Verhaltenstherapie 1993;3:53-55.
32. Marks IM, Gray S, Cohen SD, Hill R, Mawson D, Ramm EN, Stern RS: Imipramine and brief therapist aided exposure in agoraphobics having self-exposure homework. Arch Gen Psychiatry 1983;40:153-162.
33. Marks IM, Swinson RP, Basoglu M, Kuch K, Noshirvani H, O'Sullivan G, Lelliott PT, Kirby M, McNamee G, Sengun S, Wickwire K: Alprazolam and exposure alone and combined in panic disorder with agoraphobia. Br J Psychiatry 1993;162:776-787.
34. Mavissakalian MR: Differential effects of imipramine and behavior therapy on panic disorder with agoraphobia. Psychopharmacol Bull 1989;25:27-29.
35. Mavissakalian MR: Agoraphobia; in Beitman BD, Klerman MD (eds): Integrating Pharmacotherapy and Psychotherapy. Washington, American Psychiatric Press, 1991, pp 165-181.
36. Mavissakalian MR, Michelson L, Dealy RS: Pharmacological treatment of agoraphobia: Imipramine vs imipramine with programmed practice. Br J Psychiatry 1983;143:348-355.
37. Mavissakalian MR, Michelson L: Two year follow-up of exposure and imipramine treatments of agoraphobia. Am J Psychiatry 1986a;143:1106-1112.
38. Mavissakalian MR, Michelson L: Agoraphobia: Relative and combined effectiveness of therapist-assisted in-vivo exposure and imipramine. J Clin Psychiatry 1986b;47:117-122.
39. Michelson LK, Marchione K: Behavioral, cognitive, and pharmacological treatments of panic disorder with agoraphobia: Critique and synthesis. J Consult Clin Psychol 1991;59:100-114.
40. Noyes R, Garvey MJ, Cook L: Follow-up study of patients with panic disorder and agoraphobia with panic attacks treated with tricyclic antidepressants. J Affect Dis 1989;16:249-257.
41. Oehrberg S, Christiansen PE, Behnke K, Borup L, Severin B, Soegaard J, Calberg H, Judge R, Ohrstrom JK, Manniche PM: Paroxetine in the treatment of panic disorder: A randomized, double-blind, placebo-controlled study. Br J Psychiatry 1995;167:374-379.
42. O'Sullivan G, Marks IM: Long-term outcome of phobic and obsessive compulsive disorders after exposure: A review chapter; in Noyes R, Roth M, Burrows G (eds): Handbook of Anxiety. Amsterdam, Elsevier, vol 4, 1990.
43. Otto MW: Integrated treatment of panic disorder. J Clin Psychiatry 1997;58:40-42.
44. Otto MW, Pollack MH, Sachs GS, Reiter SR, Meltzer-Brody S, Rosenbaum JF: Discontinuation of benzodiazepin treatment: Efficacy of cognitive-behavioral therapy for patients with panic disorder. Am J Psychiatry 1993;150:1485-1490.
45. Pollack MH: Psychopharmacology update. J Clin Psychiatry 1997;38-40.
46. Power KG, Simpson RJ, Swanson V, Wallace LA: A controlled comparison of cognitive-behavior therapy, diazepam, and placebo, alone and in combination, for the treatment of generalized anxiety disorder. J Anxiety Dis 1990;4:267-292.
47. Rickels K, Schweizer E, Weiss S, Zavodnick S: Maintenance drug treatment for panic disorder. I: Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry 1993a;50:51-60.
48. Rickels K, Schweizer E, Weiss S, Zavodnick S: Maintenance drug treatment for panic disorder. II: Short-and long-term outcome after drug taper. Arch Gen Psychiatry 1993b;50:61-68.
49. Sanderson WC, Wetzler S: Observations on the cognitive behavioral treatment of panic disorder: Impact of benzodiazepines. Psychotherapy 1993;30:125-132.
50. Salzman C: Benzodiazepine treatment of panic and agoraphobic symptoms: use, dependence, toxicity, abuse. J Psychiatric Res 1993;17(suppl):97-110.
51. Schulze M, Osen B, Hand I: Verhaltenstherapeutische Kurzzeit-Gruppentherapie zur Versorgung von Patienten mit Angststörungen in der primärärztlichen Praxis. Verhaltenstherapie 1997;7:5-13.
52. Shear M K: Panic Disorder; in Beitman BD, Klerman MD (eds): Integrating Pharmacotherapy and Psychotherapy. Washington, American Psychiatric Press, pp 143-164.
53. Sheehan DV, Ballenger J, Jacobson G: Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 1980;37: 51-59.
54. Solyom L, Heseltine GFD, McClure DJ, Solyom C, Ledwidge B, Steinberg G: Behaviour therapy versus drug therapy in the treatment of phobic neurosis. Can Psychiatr Assoc J 1973;18:25-32.
55. Spiegel DA, Bruce TJ: Benzodiazepines and exposure-based cognitive behavior therapies for panic disorder: Conclusions from combined treatment trials. Am J Psychiatry 1997;154:773-781.
56. Spiegel DA, Bruce TJ, Gregg SF, Nuzzarello A: Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder? Am J Psychiatry 1994;151:876-881.
57. Swinson RP, Kuch K, Antony MM: Combining pharmacotherapy and behavioral therapy for panic disorder and agoraphobia; in Walker JR, Norton GR, Ross CA (eds): Panic disorder and Agoraphobia. Pacific Grove, Brooks/Cole, 1991, pp 306-334.
58. Telch MJ, Agras WS, Taylor CB, Roth WT, Gallen CC: Combined pharmacological and behavioral treatment for agoraphobia. Behav Res Ther 1985;23:325-335.
59. Telch MJ, Lucas R: Combined pharmacological and psychological treatment of panic disorder: Current status and future directions; in Wolfe BE, Maser JD (eds): Panic Disorder: A Consensus Conference. Washington, American Psychiatric Press, 1994, pp 177-197.
60. The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia: Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. Eur Arch Psychiatry 1997;247:71-80.
61. Turner SM, Beidel RG, Jacob RG: Social phobia: A comparison of behavior therapy and atenolol. J Consult Clin Psychol 1994;62:350-258.
62. Wardle J, Hayward P, Higgitt A, Stabl M, Blizard R, Gray J: Effects of concurrent diazepam treatment on the outcome of exposure therapy in agoraphobia. Behav Res Ther 1994;32:203-215.
63. Wilhelm FH, Roth WT: Acute and delayed effects of alprazolam on flight phobics during exposure. Behav Res Ther 1997;35:831-841.
64. Whitehead WE, Blackwell B, Robinson A: Effects of diazepam on phobic avoidance behavior and phobic anxiety. Biol Psychiatry 1978;13:59-64.
65. Zitrin CM, Klein DF, Woerner MG: Behavior therapy, supportive psychotherapy, imipramine and phobias. Arch Gen Psychiatry 1978;35:307-316.
66. Zitrin CM, Klein DF, Woerner MG: Treatment of agoraphobia with group exposure in vivo and imipramine. Arch Gen Psychiatry 1980;37:63-72
67. Zitrin CM, Klein DF, Woerner MG, Ross DC: Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo. Arch Gen Psychiatry 1983;40: 125-138.